News | Embolization devices | June 05, 2025

Penumbra Introduces Ruby XL System for Vascular Embolization

Penumbra's Ruby XL System for vascular embolization has received FDA clearance.

 

Penumbra Introduces Ruby XL System for Vascular Embolization

June 5, 2025 – Penumbra, Inc. has announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby XL System, the longest, largest and softest coil on the market[i]. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolization[ii].

"We’ve engineered Ruby XL to deliver more volume per coil than any other coil on the market, which may result in cost savings,” said Shruthi Narayan, President of Interventional Business at Penumbra, Inc. “Ruby XL embodies Penumbra’s commitment to innovation, delivering mechanical occlusion through more volume without sacrificing softness or deliverability.”

The Ruby XL System introduces three unique technologies — Ruby XL, POD® XL, and Packing Coil XL — all of which can be delivered through a 0.035”+ diagnostic catheter. They have a primary diameter of .030" and are designed for procedural efficiency. These coils offer more volume (up to 40mm in size) and are available in extended lengths up to 70 cm.

  • Engineered with a 3D complex shape, Ruby XL coil is designed to frame aneurysms in a variety of clinical applications.
  • POD XL features a hybrid, multistage design and is engineered with three-in-one coil occlusion technology — an anchoring segment, a framing segment, and a dense filling segment. Designed for high flow vessels, POD XL offers smooth delivery and targeted vessel control.
  • Packing Coil XL features an innovative liquid metal wave shape technology, which is designed to adjust dynamically to the size of any vessel (up to 70 cm length).

Penumbra’s Ruby portfolio of peripheral embolization products, now with Ruby XL System, provides physicians with one of the most expansive embolization offerings, enabling physicians to have the latest coil technologies and most extensive options for every case. For more information, please visit www.penumbrainc.com/products/ruby-xl.

 

[i] Data as of May 2025, Ruby XL System is the largest and longest detachable embolization coil commercially available and the only 035 packing coil commercially available.

[ii] Ruby XL is 2X larger than Ruby 020 coils and 3X larger than conventional 035 coils. Fewer coils used may potentially lead to reduced radiation exposure.

 


Related Content

News | FDA

June 12, 2025 — Viz.ai recently announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for ...

Home June 12, 2025
Home
News | FDA

Nov, 4, 2024 – R3 Vascular Inc. has announced that the U.S. Food and Drug Administration (FDA) granted investigational ...

Home November 07, 2024
Home
News | FDA

July 29, 2024 — CorVascular, a leading producer of peripheral arterial disease (PAD) / peripheral vascular disease (PVD) ...

Home July 29, 2024
Home
News | FDA

July 2, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott has issued a correction for its ...

Home July 02, 2024
Home
News | FDA

June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary ...

Home June 18, 2024
Home
News | FDA

June 17, 2024 — Elutia Inc., a pioneer in drug-eluting biomatrix products, today announced that its Antibiotic-Eluting ...

Home June 17, 2024
Home
News | FDA

June 13, 2024 — Xeltis, a leading developer of transformative implants that enable the natural creation of living and ...

Home June 13, 2024
Home
News | FDA

June 3, 2024 — Heuron, a specialized medical AI startup focused on brain and neurological disorders based in South Korea ...

Home June 03, 2024
Home
News | FDA

May 17, 2024 — Implicity, a leader in remote patient monitoring and cardiac data management solutions, announced it has ...

Home May 17, 2024
Home
News | FDA

May 15, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling the HeartMate 3 LVAS by ...

Home May 15, 2024
Home
Subscribe Now